Deborah Telman, Gilead Sciences Inc.'s top lawyer for the past three years, is relinquishing her duties as general counsel ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Deborah Telman is exiting months after the company paid $202 million to settle allegations that it provided illegal kickbacks ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining ...

Gilead Sciences ( ($GILD) ) has provided an update. On November 19, 2025, Gilead Sciences announced that Deborah H. Telman will step down from her ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Gilead has reported that its phase 3 ASCENT-07 trial evaluating Trodelvy (sacituzumab govitecan-hziy) as a first-line ...

Recent analyst updates have led to a slight increase in Gilead Sciences’ fair value price target, moving from $127.23 to $129 ...

Around 1,000 doses of Gilead Sciences' HIV prevention drug, lenacapavir, were sent to Zambia and Eswatini under a U.S.